Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
ZIM LABORATORIES LIMITED is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 3 distinct art units, indicating a broad reach within the patent office. This distribution suggests that the company is pursuing multiple technical paths or distinct inventions that have been categorized into different examination groups. Managing three separate lines of inquiry requires a robust administrative framework to track varying deadlines and procedural requirements across the Biotechnology & Pharmaceuticals sector.
The busiest examiner for the portfolio is LEE, WILLIAM Y, who is assigned 1 pending office action. This indicates that the 3 pending office actions are distributed among the 3 distinct examiners currently reviewing the company's applications. The involvement of 3 distinct art units implies that the subject matter spans different specialized areas, which may result in a variety of technical challenges. Practitioners must coordinate strategies across these different units and examiners to ensure consistent prosecution across the portfolio. This diversity in examination provides the company with multiple perspectives on its technical disclosures while navigating the specific requirements of LEE, WILLIAM Y.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
| MITCHELL, EDWIN COLEMAN | 1 | 32.1% | +64.8% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17047063 | COMPOSITION OF ACTIVE INGREDIENT LOADED EDIBLE INK AND METHODS OF MAKING SUITABLE SUBSTRATES FOR ACTIVE INGREDIENT PRINTING ON ORODISPERSIBLE FILMS | MITCHELL, EDWIN COLEMAN | 53d overdue |
| 15580684 | MUCOSAL DELIVERY OF VITAMIN B12 | HELM, CARALYNNE E | 15d overdue |
| 17922921 | NOVEL EXTENDED RELEASE COMPOSITION OF TOFACITINIB, ITS DERIVATIVES AND SALTS | LEE, WILLIAM Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17047063 | COMPOSITION OF ACTIVE INGREDIENT LOADED EDIBLE INK AND METHODS OF MAKING SUITABLE SUBSTRATES FOR ACTIVE INGREDIENT PRINTING ON ORODISPERSIBLE FILMS | MITCHELL, EDWIN COLEMAN | 53d overdue |
| 15580684 | MUCOSAL DELIVERY OF VITAMIN B12 | HELM, CARALYNNE E | 15d overdue |
| 17922921 | NOVEL EXTENDED RELEASE COMPOSITION OF TOFACITINIB, ITS DERIVATIVES AND SALTS | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1619 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17922921 | NOVEL EXTENDED RELEASE COMPOSITION OF TOFACITINIB, ITS DERIVATIVES AND SALTS | LEE, WILLIAM Y | 1623 | §103§112 | Non-Final OA | — | Pending | Nov 02, 2022 |
| 17047063 | COMPOSITION OF ACTIVE INGREDIENT LOADED EDIBLE INK AND METHODS OF MAKING SUITABLE SUBSTRATES FOR ACTIVE INGREDIENT PRINTING ON ORODISPERSIBLE FILMS | MITCHELL, EDWIN COLEMAN | 1619 | §102§103§112 | Final Rejection | 53d overdue | Pending | Oct 12, 2020 |
| 15580684 | MUCOSAL DELIVERY OF VITAMIN B12 | HELM, CARALYNNE E | 1615 | §112 | Non-Final OA | 15d overdue | Pending | Dec 07, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial